Coengineering specificity, safety, and function into T cells for cancer immunotherapy.
Level 5 - mechanism / opinion, no new human data
Narrative review / mechanism-based overview with no primary clinical or systematic data.
PubMed 37548063 · doi:10.1111/imr.13252
What was done
This narrative review summarizes challenges facing adoptive T-cell transfer (ACT)—including tumor-infiltrating lymphocytes, TCR-engineered T cells, and CAR-T cells—particularly in solid tumors and relapse settings. It outlines post-infusion biological hurdles (poor trafficking, exhaustion, immunosuppressive tumor microenvironments, antigen loss, tumor intrinsic resistance, and toxicity) and reviews recent T-cell coengineering strategies, synthetic tools, receptors, and gene-cargo designs aimed at improving cell therapy safety and potency.
What was found
The abstract provides no empirical numbers or quantitative data. It qualitatively identifies core mechanisms driving ACT failure and highlights engineering solutions such as affinity-optimized TCRs, novel CAR architectures, and multi-functional gene-cargo modifications designed to overcome suppressive microenvironments and engage endogenous immune responses.
Why it matters
Adoptive cell therapies show limited efficacy in solid tumors and high relapse rates in certain hematologic cancers; understanding and categorizing synthetic coengineering strategies clarifies how next-generation cell therapies can overcome tumor-mediated immunosuppression.
Limits
As a narrative review, it lacks a systematic literature search, standardized study selection methodology, or meta-analytic synthesis. No primary human or preclinical quantitative outcome data are reported in the abstract.
Cited by
- context CAR-T cell therapies involve engineering T cells with specialized receptors to target tumors, but often fail in patients due to the immune system shutting down or cells failing to eliminate the tumor.